Archive: Company News
Ebenbuild Appoints Charles A. Taylor, PhD as Chairman of the Board
— World renowned researcher and leader in predictive, simulation-based medicine to support further growth and strengthen footprint in the U.S.
Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that Charles A. Taylor, PhD has been appointed Chairman of the Board. Dr. Taylor is a pioneer in the field of predictive, simulation-based medicine where he applied computational fluid dynamics to predict outcomes of cardiovascular interventions in individual patients.
ANEUVO to Showcase Breakthrough Neuromodulation Device ExaStim® at MEDICA 2024
— Novel Device with FDA Breakthrough Device Designation to Treat Chronic Spinal Cord Injuries
— Attendees Invited to Visit Booth Hall 10 / H44 to Explore FDA Breakthrough Device Designation Technology
The next step in restoring mobility and independence for individuals with chronic spinal cord injuries is almost here. ANEUVO, a company dedicated to improving lives through innovative therapies, will showcase its ExaStim® Stimulation System (‘ExaStim’) at the MEDICA 2024 conference. ExaStim is a portable, customizable, non-invasive spinal cord stimulation solution designed to help people with chronic spinal cord injuries regain motor function. Read more…
AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
— Lead product AMYNOPEP achieves proof-of-principle in exploratory clinical study
— AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical enzymes on the lining of the intestinal brush border
AMYRA Biotech AG (“AMYRA”), a company developing novel, oral digestive enzyme therapeutics for gastrointestinal diseases announced the peer-reviewed publication of its clinical proof-of-principle study with its lead product AMYNOPEP in Frontiers in Immunology – Nutritional Immunology(https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1425982/full). AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical endogenous enzymes on the lining of the small intestine. AMYNOPEP is designed to break down hard-to-digest gluten peptides into harmless and absorbable single amino acids and dipeptides, thereby supporting individuals with gluten-related health disorders in avoiding exposure to inflammatory peptides. Read more…
Preliminary Data of BellaSeno’s Clinical Trial on Scaffold-Guided Breast Regeneration Presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA
— Performance: Statistically significant superiority over fat grafting, with breast volume retention twice as high
— Safety: BellaSeno’s scaffolds are safe and improve patient satisfaction and well-being
BellaSeno GmbH, an ISO 13485 certified tissue regeneration company developing resorbable scaffolds using additive manufacturing technologies, today announced that new clinical data from the first interim report of its ongoing study evaluating the use of BellaSeno’s 3D-printed resorbable breast scaffolds (ClinicalTrials.gov ID NCT05437757) were presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA, USA (Sept. 26 – 29, 2024).